Myocardial Infarction
Conditions
Keywords
Sevoflurane, Ck-MB
Brief summary
Increase in CK-MB after percutaneous coronary angioplasty more than 100% of baseline can represents a problem to the patients resulting in increase of morbidity and mortality. Patients submitted of coronary angioplasty procedures can release in varying degrees of creatine kinase, MB isoform (CK - MB), on the order of 30% of all angioplasty. Possibly patients who will receive sevoflurane experience a higher level of cardiac cell protection with lower incidence in the release of CK - MB values in excess of 100% baseline.
Detailed description
Several published clinical studies have shown the benefit of using inhaled anesthetic agents in patients undergoing coronary artery bypass graft(CABG). These benefits involve functional state of the heart and reduction damage to the organ. These events are related to intracellular phenomena that result in intracellular calcium homeostasis giving physical and functional benefits to the heart. Also disclosed is a modulation of the inflammatory response to endothelial level with resulting protective character to the coronary bed. Patients submitted of coronary angioplasty procedures can release in varying degrees of creatine kinase, MB isoform (CK - MB), on the order of 30% of all angioplasty. Even in smaller increases than 3 times baseline, a criterion that defines myocardial infarction, clinical impact can already be found. Increase in CK-MB more than 100% of baseline can represents a problem to the patients. This elevation of CK - MB is associated with various factors such as age, characteristic of the lesion, clinical status of the patient, inferring that endovascular procedures of coronary, simple or complex, have associated myocardial damage, which depending on the intensity of the damage, results in increased morbidity and mortality. BACKGROUND AND OBJECTIVES: Check for reduction in the percentage of patients that release CK -MB at levels above the 100% baseline in patients anesthetized with sevoflurane compared to the control group. Possibly patients who will receive sevoflurane experience a higher level of cardiac cell protection with lower incidence in the release of CK - MB values in excess of 100% baseline.
Interventions
DRUGsevoflurane
compare effect of sevoflurane when administered before PCI
Sponsors
Instituto Dante Pazzanese de Cardiologia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Both gender. 2. Patients with coronary artery disease candidates for coronary angioplasty stent. 3. Cardiac catheterization on an urgent basis. 4. Coronary angioplasty in elective and urgency. 5. Age less than 80 years.
Exclusion criteria
1. Patients aged greater than or equal of 80 years. 2. Angioplasty balloon catheter statement. 3. Myocardial infarction with ST-segment elevation. 4. Angioplasty in saphenous vein grafts in patients after surgical revascularization. 5. Patient pregnant. 6. Dialytic insufficiency renal. 7. Patients submited a urgent cardiac catheterization but not progress with coronary angioplasty stent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure level of Ck-MB in all patients | 24 hours after coronary intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Length of stay in hospital | 30 days after coronary intervention | It will be quantified the length of hospital stay of patients who underwent coronary intervention checking if there is difference between groups |
| Length of stay in Intensive Care Unit (UCI) | 30 days after coronary intervention | The length of stay in UCI will be quantified if patients who underwent coronary intervention are referred to this sector |
| mortality rate | 1 year after coronary intervention | — |
Countries
Brazil
Outcome results
None listed